HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology
Business Wire•21/10/2026•08:31 ET
0
Key Highlights
- ➤HEADSTART-ACS enrolled 486 patients ahead of schedule
- ➤Data analysis underway; results anticipated at a cardiology conference in 2027
- ➤HeartBeam heart-attack detection studies now exceed 600 patients
- ➤U.S. pivotal heart-attack detection study planned for Q1 2027
- ➤HeartBeam System is not currently cleared for heart-attack detection
Expert Statements
Iwan Dakota, Director of the National Cardiovascular Center Harapan Kita
“HeartBeam’s technology has the potential to save many lives. In cases of acute myocardial infarction, time to medical intervention is a critical determinant of patient survival. We welcome and strongly support the completion of this study at our hospital and look forward to its results with great interest.”
Branislav Vajdic, Founder and President of HeartBeam
“Indonesia is a prime example of why heart attack assessment outside the hospital is a significant need”
HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology
* HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million people
Get started
Create a free account to read the full story.